Paul Talks Science

Across the world, some individuals are able to naturally control HIV without requiring antiretroviral therapy, due to the uniqueness of their genetic composition. Several of these individuals have been identified in South Africa which has the world's highest HIV/AIDS burden. Dr Veron Ramsuran, associate professor at the University of KwaZulu-Natal is leading a team that also includes researchers from the South African Medical Research Council (SAMRC) to study this crucial population in South Africa, whose unique genetic makeup could contain the secrets to more effective AIDS prevention tools. The ultimate goal is to develop therapeutic interventions that mimic the natural protective mechanisms found in elite controllers. In this episode, Dr Veron speaks to Paul about the landmark research that highlights the global relevance of the differences in genetic factors between African and other populations, highlighting the importance of studying diverse populations.

In this conversation, Paul Adepoju hosts Alukhethi Singo-Ragimana from MGI Tech. They discuss the unique features of MGI's sequencing technology, its applications in HIV genotyping and drug resistance surveillance, and the challenges and solutions in the sequencing ecosystem in Africa. They also talk about MGI's plans for South Africa and its involvement in the Africa-wide genomic initiative. The conversation highlights the affordability and competitiveness of genomic sequencing technologies, the impact of the COVID-19 pandemic on sequencing adoption, and the potential of sequencing to transform healthcare in Africa.

In this episode, we explore a groundbreaking development in Nigeria's healthcare system. The Nigerian government has officially declared cancer a notifiable disease, mandating all public and private healthcare providers to report cancer cases to a centralized registry. This initiative aims to create a comprehensive database that accurately reflects the burden of cancer in Nigeria, enabling better resource allocation, policy formulation, and monitoring of interventions.

Our guest is Her Excellency, Dr. Zainab Shinkafi-Bagudu, a renowned cancer advocate, board member of the Union for International Cancer Control, and founder of the Medicaid Cancer Foundation. She provides valuable insights into the significance of this new mandate, the challenges and opportunities it presents, and the potential for improved cancer care and outcomes in Nigeria.

Join us as we delve into the details of this important story, the current state of cancer data in Nigeria, and the collaborative efforts needed to enhance cancer diagnosis and treatment.

Read the full story, now live, by following this link.

Topics Discussed:

Don't miss this informative episode!

Guest: Zainab Shinkafi-Bagudu, cancer advocate, board member of the Union for International Cancer Control, and founder of the Medicaid Cancer Foundation

Host: Paul Adepoju, PhD

Subscribe, rate, and review Paul Talks Science to stay updated with the latest episodes.

In this inaugural episode of "The Future Tense," host Paul Adepoju sits down with Health Minister Dr. Shane Reti and Cancer Society of New Zealand CEO Dr. Rachael Hart to discuss a groundbreaking development in New Zealand's healthcare system. The coalition government has announced a substantial funding boost for cancer treatments, allowing Pharmac, the country's drug-buying agency, to introduce 26 new cancer treatments as part of 54 new medicines.

Dr. Reti and Dr. Hart delve into the details of this transformative initiative, the expected impact on cancer patients, and the broader implications for the healthcare landscape. They also explore the importance of holistic support for cancer patients, prioritization within the healthcare budget, and the future of cancer care and research in New Zealand.

This episode is based on an interview conducted by Paul Adepoju for a story published in The Lancet Oncology. For more insights, check out the link to the full article in the episode description. Join us as we kick off "The Future Tense" with a compelling discussion on the future of cancer treatment in New Zealand.